Pharmaceutical Benefits Scheme (PBS) Application Made for Treatment of Metastatic Pancreatic Cancer

You might be interested in submitting your views on an application that has been made to include Onivyde® (nal-IRI) on the Pharmaceutical Benefits Scheme (PBS).

The manufacturer has made an application to the Pharmaceutical Benefits Advisory Committee (PBAC) so that you are not charged if you receive treatment with Onivyde® (nal-IRI) as a patient with metastatic pancreatic cancer.

As part of the process of considering approval by the PBAC, anyone can submit comments via an online form, which you can access here until October 5th 2016.

The manufacturer reports that the research shows that the addition of Onivyde with 5-fluorouracil (5-FU) and leucovorin increased overall survival from 4.2 months to 6.1 months.

To read more about the research click here.